(ANSA) – TURIN, SEPTEMBER 27 – Anti-Cgrp monoclonal antibodies represent the main innovation of recent years in migraine prophylaxis: the benefits for patients were discussed at the symposium, sponsored in a non-conditional manner by Teva, at the 38th congress of the Sisc, the Italian Society for the Study of Headaches, underway in Turin.
“The anti-Cgrp monoclonal antibodies for the preventive treatment of migraine, which we have been using for five years now, have shown an excellent tolerability and efficacy profile”, explained Dr. Luigi Francesco Iannone, researcher on the sidelines of the symposium of the Department of Health Sciences of the University of Florence.
In clinical practice it is becoming common to follow migraine patients who simultaneously take other therapies for chronic pathologies: for this reason there is great attention to possible, and currently unknown, pharmacological interactions within the class of anti-Cgrp monoclonal antibodies.
“Recently – adds Dr. Iannone – precisely with Sisc, we published a new study which demonstrates how neither tolerability nor efficacy are affected by the co-administration for more than six months of a monoclonal anti-Cgrp antibody with another type of monoclonal antibody, administered for other pathologies”. (HANDLE).
2024-09-27 15:13:36